Valeur202020212022202320242025Total du passif825.05 K7.44 M4.75 M3.52 M3.11 M2.52 MTotal des capitaux propres9.57 M4.36 M26.6 M5.76 M5.05 M3.83 MTotal du passif et des capitaux propres10.39 M11.8 M31.35 M9.28 M8.16 M6.34 MDette totale198.06 K0————Dette nette-9.69 M-11.42 M————
GeoVax Labs, Inc. - Common Stock
GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles in the person being vaccinated.